ArticleBritish journal of cancer2014
Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Risk-reducing medications for primary breast cancer: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Pooled it
- Trial
- Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.Cancer prevention research (Philadelphia, Pa.) · 2015Trial
- The Influence of Resource Constraints on Risk-Related Conversations With Specialists Among a Community-Based Sample of Women at High Risk for Breast Cancer.Cancer medicine · 2026Article
- A pilot study of a behavior-change intervention for preventive therapy among women at high risk for invasive breast cancer.BMC medical informatics and decision making · 2026Article
- Provider effects and racial inequities in breast cancer risk-management adoption: Findings from a community-based study of high-risk women.Patient education and counseling · 2026Article
- Evaluation of a telehealth service to support breast cancer prevention medication uptake: a protocol of a mixed methods study.BMJ open · 2025Article
- Perceptions of chemoprevention among individuals at high risk of oral cancer: qualitative study within the UK-based SAVER trial.BMJ open · 2025Article
- A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.Breast cancer research and treatment · 2025Review
- Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome.JCO precision oncology · 2024Article
- A novel preclinical model of the normal human breast.Journal of mammary gland biology and neoplasia · 2024Article
- Review
- Article
- Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).British journal of cancer · 2023Article
- Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models.International journal of molecular sciences · 2023Article
- Barriers and facilitators to using aspirin for preventive therapy: a qualitative study exploring the views and experiences of people with Lynch syndrome and healthcare providers.Hereditary cancer in clinical practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomised trials of tamoxifen versus placebo indicate that tamoxifen reduces breast cancer risk by approximately 33%, yet uptake is low. Approximately 10% of women in our clinic entered the IBIS-I prevention trial. We assess the uptake of tamoxifen in a consecutive series of premenopausal women not in a trial and explore the reasons for uptake through interviews.
methodsAll eligible women between 33 and 46 years at ≥17% lifetime risk of breast cancer and undergoing annual mammography in our service were invited to take a 5-year course of tamoxifen. Reasons for accepting (n=15) or declining (n=15) were explored using semi-structured interviews.
resultsOf 1279 eligible women, 136 (10.6%) decided to take tamoxifen. Women >40 years (74 out of 553 (13.4%)) and those at higher non-BRCA-associated risk were more likely to accept tamoxifen (129 out of 1109 (11.6%)). Interviews highlighted four themes surrounding decision making: perceived impact of side effects, the impact of others' experience on beliefs about tamoxifen, tamoxifen as a 'cancer drug', and daily reminder of cancer risk.
conclusionsTamoxifen uptake was similar to previously ascertained uptake in a randomised controlled trial (IBIS-I). Concerns were similar in women who did or did not accept tamoxifen. Decision making appeared to be embedded in the experience of significant others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.